Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

ASND has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, October 8th. Morgan Stanley initiated coverage on shares of Ascendis Pharma A/S in a research note on Thursday, July 3rd. They issued an “overweight” rating and a $250.00 price objective for the company. Stifel Nicolaus boosted their price objective on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. Bank of America boosted their price objective on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Finally, Wedbush boosted their price objective on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $249.80.

Ascendis Pharma A/S Stock Down 2.5%

ASND stock opened at $205.21 on Friday. The company has a market capitalization of $12.66 billion, a price-to-earnings ratio of -39.77 and a beta of 0.41. Ascendis Pharma A/S has a 12 month low of $118.03 and a 12 month high of $216.45. The firm has a 50 day moving average of $199.34 and a two-hundred day moving average of $178.27.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.49. The business had revenue of $216.28 million during the quarter, compared to the consensus estimate of $163.17 million. On average, research analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Large investors have recently bought and sold shares of the stock. Compagnie Lombard Odier SCmA acquired a new position in Ascendis Pharma A/S during the 2nd quarter valued at $39,000. First Horizon Advisors Inc. acquired a new position in Ascendis Pharma A/S during the 2nd quarter valued at $41,000. Brooklyn Investment Group increased its holdings in Ascendis Pharma A/S by 332.9% in the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 273 shares during the period. Hantz Financial Services Inc. increased its holdings in Ascendis Pharma A/S by 291.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 262 shares during the period. Finally, Farther Finance Advisors LLC increased its holdings in Ascendis Pharma A/S by 115.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 256 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.